Protease inhibitor

Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir

Retrieved on: 
Wednesday, July 28, 2021

New York, NY, and Tel Aviv, ISRAEL, July 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has retained the services of Innvocept Global Solutions, an Indian clinical research organization (CRO), to manage 2 adaptive design Phase 2/3 clinical trials the Company is preparing to initiate with its joint venture partner NLC Pharma of its proprietary oral antiviral 3CL protease inhibitor drug candidate Tollovir™ for the treatment of non-hospitalized and hospitalized COVID-19 patients in India. Engaging a CRO is the first step of the regulatory process in India.  The Company expects enrollment for both trials to begin in the third quarter of 2021 with initial, trial expansion-enabling data expected in the fourth quarter of 2021 that could make each trial become part of the Company’s global pivotal clinical development program for Tollovir that would begin in the fourth quarter of 2021.

Key Points: 
  • This trial opened enrollment in April 2021 and is also evaluating the use of TolloTest as a companion diagnostic for antiviral therapy.
  • TolloTest is the Companys proprietary 3CL protease biomarker assay that is being developed as a more accurate measure of viral infection, load and infectiousness in COVID-19 patients.
  • This dual mechanism makes Tollovir unique among the emerging class of 3CL protease inhibitors currently in development.
  • For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials.

Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment

Retrieved on: 
Friday, July 23, 2021

While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.

Key Points: 
  • While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.
  • GC376 is a protease inhibitor, designed to block the replication process and stop the virus from spreading.
  • GC376 has the potential to be a One Health medicine, providing therapeutic benefits to both pets and people.
  • Anivive has filed a pre-Investigational New Drug request with the Food and Drug Administration to evaluate GC376 as a post-infection treatment of COVID-19 in humans.

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim

Retrieved on: 
Thursday, July 22, 2021

The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim.

Key Points: 
  • The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim.
  • The Company intends to establish a monthly subscription model as part of its marketing launch campaign for Tollovid Daily immune system support.
  • Tollovid and Tollovid Daily are both 3CL protease inhibitor products developed under a joint venture with NLC Pharma.
  • We are very excited with the new FDA Certificate of Free Sale for Tollovid Daily, the newest member of our Tollovid dietary supplement product line, said Gerald E. Commissiong, President & CEO of Todos Medical.

Exscientia Accelerates COVID-19 Drug Discovery Using AI

Retrieved on: 
Thursday, July 8, 2021

This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform.

Key Points: 
  • This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform.
  • Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class of inhibitors targeting the SARS-CoV-2s main protease enzyme, Mpro, also known as 3CLpro, the causative agent of COVID-19.
  • The virus protease inhibitors will be designed using Exscientias AI-driven drug discovery platform, which delivers optimised compounds, fulfilling complex design goals faster and more effectively than with conventional drug discovery methods.
  • Exscientia has built a track record of improving and accelerating drug discovery by advancing the first three completely AI-designed small molecule drug candidates into clinical trials.

U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C

Retrieved on: 
Thursday, June 10, 2021

The recommended dosage of Epclusa in children ages 3 years and older is based on weight.

Key Points: 
  • The recommended dosage of Epclusa in children ages 3 years and older is based on weight.
  • Sofosbuvir/velpatasvir is the only protease inhibitor-free, pangenotypic HCV regimen approved for patients as young as 3 years of age.
  • Of the seven patients who did not achieve cure, all discontinued treatment within one to 20 days of starting treatment.
  • The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned

Retrieved on: 
Wednesday, June 9, 2021

The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.

Key Points: 
  • The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.
  • Sunshine Biopharmas protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home.
  • We are moving the project forward as fast as possible, albeit within the constraints of science, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders

Retrieved on: 
Monday, May 31, 2021

In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.

Key Points: 
  • In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.
  • In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
  • www.vivoryon.com
    Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties.
  • The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release.

Global HIV Drugs Market Report 2021: Long-term Forecast to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021

b'The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H.

Key Points: 
  • b'The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H.
  • HIV drugs are repurposed to treat Covid 19 infections.
  • Global HIV Drugs Historic Market, 2015-2020, $ Billion\n5.2.
  • Global HIV Drugs Forecast Market, 2020-2025F, 2030F, $ Billion\n'

Accurate Diagnostic Solutions Remain Vital to Overcoming the Pandemic

Retrieved on: 
Tuesday, May 4, 2021

Ahmad Gaber, Chief Executive Officer of Wellhealth and founder of GoGetTested, explained according to Healthline that "testing is important for two reasons.

Key Points: 
  • Ahmad Gaber, Chief Executive Officer of Wellhealth and founder of GoGetTested, explained according to Healthline that "testing is important for two reasons.
  • Tollovid, a potent 3CL protease inhibitor botanical product, is a dietary supplement that helps to support and maintain healthy immune function.
  • You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
  • Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed.

Accurate Diagnostic Solutions Remain Vital to Overcoming the Pandemic

Retrieved on: 
Tuesday, May 4, 2021

Ahmad Gaber, Chief Executive Officer of Wellhealth and founder of GoGetTested, explained according to Healthline that "testing is important for two reasons.

Key Points: 
  • Ahmad Gaber, Chief Executive Officer of Wellhealth and founder of GoGetTested, explained according to Healthline that "testing is important for two reasons.
  • Tollovid, a potent 3CL protease inhibitor botanical product, is a dietary supplement that helps to support and maintain healthy immune function.
  • You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
  • Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed.